

Supplementary Table 1 | Selected ongoing clinical trials of next-generation thalidomide analogues

Agent	Disease	Treatment approach	Study phase	ClinicalTrials.gov identifier
CC-90009	R/R high-risk MDS or R/R AML	Single agent	Phase I	NCT02848001
	Newly diagnosed or R/R AML	In combination with venetoclax (BCL2 inhibitor) and azacitidine (HMA) or with gilteritinib (FLT3 inhibitor)	Phase I/II	NCT04336982
Avadomide (CC-122)	Advanced-stage melanoma (naive or refractory to PD-1 inhibition)	In combination with nivolumab (anti-PD-1 antibody)	Phase II	NCT03834623
	Advanced-stage HCC (after one prior line of therapy)	In combination with nivolumab	Phase I/II	NCT02859324
	Newly diagnosed DLBCL with poor-risk factors	In combination with R-CHOP chemotherapy	Phase I	NCT03283202
	Treatment-naive or R/R CLL or SLL	Single-agent, or in combination with ibrutinib (BTK inhibitor) or obinutuzumab (anti-CD20 antibody)	Phase I/II	NCT02406742
	R/R DLBCL or R/R FL (naive or refractory to lenalidomide)	In combination with obinutuzumab	Phase Ib	NCT02417285
	R/R DLBCL or R/R FL (naive or refractory to lenalidomide)	In combination with rituximab (anti-CD20 antibody) and/or either onasertib (CC-223; mTOR inhibitor) or spebrutinib (CC-292; BTK inhibitor)	Phase Ib	NCT02031419
	R/R B cell malignancies	In combination with JCAR017 (autologous anti-CD19 4-1BB CAR T cell product)	Phase I/II	NCT03310619
	R/R advanced-stage solid tumours, NHL or MM	Single agent	Phase I	NCT01421524
	Advanced-stage solid tumours or NHL	Single agent	Phase I	NCT02509039
Iberdomide (CC-220)	R/R MM	Single agent, or in combination with daratumumab (anti-CD38 antibody), bortezomib (PI), carfilzomib (PI) and/or dexamethasone (corticosteroid)	Phase Ib/IIa	NCT02773030
	R/R MM	In combination with low-dose cyclophosphamide (chemotherapy) and dexamethasone	Phase II	NCT04392037
	Newly diagnosed MM	Single-agent maintenance after ASCT	Phase II	NCT04564703
	R/R lymphomas	Single agent, or in combination with rituximab or obinutuzumab	Phase I/II	NCT04464798
	R/R B cell malignancies	In combination with JCAR017 (autologous anti-CD19 4-1BB CAR T cell product)	Phase I/II	NCT03310619
CC-92480	R/R MM	Single agent, in combination with dexamethasone	Phase I	NCT03374085
	Newly diagnosed or R/R MM	In combination with dexamethasone plus either daratumumab, bortezomib or carfilzomib	Phase I/II	NCT03989414

Trials involving patients with cancer and noted as being 'not yet recruiting', 'active, not yet recruiting', 'recruiting' or 'completed' with no results posted were retrieved from the ClinicalTrials.gov database. AML, acute myeloid leukaemia; ASCT, autologous haematopoietic stem cell transplantation; CLL, chronic lymphocytic leukaemia; DLBCL, diffuse large B cell lymphoma; FL, follicular lymphoma; HCC, hepatocellular carcinoma; HMA, hypomethylating agent; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; PI, proteasome inhibitor; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R/R, relapsed and/or refractory; SLL, small lymphocytic leukaemia.